Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vistra Corp (VST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vistra Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Vistra Corp trades at $152.07 (market cap $52.51B). The key difference: Vistra Corp is far larger — about 11.7× ACADIA Pharmaceuticals Inc.'s market cap, and Vistra Corp pays a 0.59% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VST | |
|---|---|---|
Market Cap | $4.49B | $52.51B |
Sector | Health | Technology |
52-Week High | $28.06 | $217.92 |
52-Week Low | $20.06 | $134.71 |
Enterprise Value | $3.69B | $74.26B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Vistra Corp (VST) trades at $157.22, up 4.08% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but faces cash flow challenges. Revenue growth from $17.74B to $19.4B and improved net margins to 11.52% reflect operational strength, supported by AI-driven power demand catalysts and a $6.3B buyback program.
Outlook remains positive with 91% analyst buy ratings and a $230.50 price target, though technical resistance near $159 and volatile earnings pose near-term risks. Long-term growth is fueled by nuclear/renewable expansion, but investors should monitor execution on guidance and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
